Skip to content
Follow us on
Facebook Twitter
  • Home
  • Products
    • Live S&P Messenger
    • Williams Edge Futures
    • Williams Edge S&P
    • Williams Edge Plus
    • Squares Principal
    • Reflected Wave
  • Customer Login
  • Past Performance
  • Trial
  • Testimonials
  • Calendar
  • Contact Us
Menu
  • Home
  • Products
    • Live S&P Messenger
    • Williams Edge Futures
    • Williams Edge S&P
    • Williams Edge Plus
    • Squares Principal
    • Reflected Wave
  • Customer Login
  • Past Performance
  • Trial
  • Testimonials
  • Calendar
  • Contact Us
$0.00 Cart

07/23/2015 – Alnylam Pharmaceuticals

  • July 23, 2015
  • Alnylam Pharmaceuticals

Issued: 07/13/2015

Alnylam pharmaceuticals, ALNY:

1. Last week (week of July 6) we noted that a weekly close above $118.00 in Alnylam pharmaceuticals should be bought for further advance and test/attempt at $129.00, or higher.

2. Last week closed at $121.77 (above $118) indicating new long entry.

3. Partial long position exit should be taken at/near current prices (current price $125.64). The remainder should be held for a test/attempt at $129.00. Any final exit will be messaged in a subsequent update.

4. A protective sell stop should be placed at $123.16. This stop will be moved higher as the market continues to confirm.

David Williams

Issued: 07/23/2015

Alnylam pharmaceuticals, ALNY:

1. During the week of July 6 we noted that a weekly close above $118.00 in Alnylam pharmaceuticals should be bought for further advance and test/attempt at $129.00, or higher.

2. ALNY completed its advance to $129.00 final upside target, completing the trade. Will message any further entry or indication in Alnylam pharmaceuticals.

David Williams

CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

Members of

PageTrader, Ltd. is a BBB Accredited Business Consultant in Las Vegas, NV

Links

  • Trading Disclaimer
  • Privacy Policy
  • About Us
  • Cancellation and Refund Policy
  • Contact Us

 

  • Home
  • Market Forecasting Products
  • Customer Login
  • Webinar Calendar
CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.
CLICK HERE TO READ OUR FULL TRADING DISCLAIMER
Copyright ©2000-2022 PageTrader, Ltd. All Rights Reserved.